Now there is an opportunity for your friends, family members, neighbors and coworkers who want to fight back against prostate cancer in your honor? They have the opportunity to take part in an historic research effort being conducted by the American Cancer Society where they can indeed fight back in a very easy way. The [...]
The normal protocol when chemotherapy is administered to men who have androgen-independent prostate cancer (AIPC) is to continue the androgen deprivation program despite its failure to any longer suppress the cancer’s growth. A study published by the Department of Medical Oncology, St Bartholomew's Hospital, London, UK, examined whether it was possible to re-induce hormone sensitivity [...]
Today’s New York Times carried a story written by Reed Abelson entitled “Financial Ties Are Cited as Issue in Spine Study.” The story explained that some of the nation’s most prominent spine surgeons hailed as a medical breakthrough a study of nearly 240 patients with lower back pain. The doctors said that Prodisc, an artificial [...]
Yale University in Connecticut is conducting a very interesting phase II clinical trial on a drug called Phenoxodiol for men with castrate and noncastrate prostate cancer. Phenoxodiol has been undergoing trials in Australia with promising results. The good news is that most men do not seem to have any negative side effects from the drug. [...]
Earlier this month Novacea, Inc. (NASDAQ: NOVC) announced that it has prematurely ended its Phase 3 ASCENT-2 clinical trial of Asentar, also known as DN-101. Asentar had been the company's lead investigational cancer therapy for the treatment of those of us who are androgen-independent (AIP). The Data Safety Monitoring Board (DSMB) for the clinical study [...]
